Tag: quarterly report

NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) a leading developer, owner, and operator of industrial-scale data centers, today announced that its wholly-owned subsidiary, Stingray Compute LLC (the “Issuer”), has priced a $810.0 million offering of 6.000% senior secured notes due 2031 (the “Notes”) at a price equal to 99.750% of their principal amount. The Notes will be sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside of the United States pursuant to Regulation S under the Securities Act. The offering is expected to close on June 15, 2026, subject to customary closing conditions.

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.  

KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the “Annual Meeting”), including shareholder meeting activities and a company update, will be accessible by Zoom webinar (the “Webinar”). The in-person meeting will be held on Thursday, June 18, 2026 at Perkins Place Office Building, located at 525 Portland Street, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time.

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Elauwit Connection, Inc. (NASDAQ: ELWT) resulting from allegations that Elauwit may have issued materially misleading business information to the investing public.

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

BALLERUP, Denmark, June 04, 2026 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company specializing in advanced ceramic filtration solutions, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of approximately $20 million, prior to deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on June 8, 2026, subject to satisfaction of customary closing conditions.

Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital